117 related articles for article (PubMed ID: 38579402)
1. A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients.
Rossi S; Tatangelo V; Dichiara M; Butini S; Gemma S; Brogi S; Pasquini S; Cappello M; Vincenzi F; Varani K; Lopresti L; Malchiodi M; Carrara C; Gozzetti A; Bocchia M; Marotta G; Patrussi L; Carullo G; Baldari CT; Campiani G
Biomed Pharmacother; 2024 May; 174():116537. PubMed ID: 38579402
[TBL] [Abstract][Full Text] [Related]
2. A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis.
Vanni F; Lopresti L; Zurli V; Kabanova A; Cattaneo F; Sicuranza A; Gozzetti A; Gemma S; Zisterer DM; Bocchia M; Campiani G; Baldari CT; Butini S; Ulivieri C
Pharmacol Res; 2021 Dec; 174():105965. PubMed ID: 34732370
[TBL] [Abstract][Full Text] [Related]
3. Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Cattaneo F; Patrussi L; Capitani N; Frezzato F; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncotarget; 2016 Aug; 7(35):57086-57098. PubMed ID: 27494881
[TBL] [Abstract][Full Text] [Related]
4. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
5. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia.
Capitani N; Lucherini OM; Sozzi E; Ferro M; Giommoni N; Finetti F; De Falco G; Cencini E; Raspadori D; Pelicci PG; Lauria F; Forconi F; Baldari CT
Blood; 2010 May; 115(18):3726-36. PubMed ID: 20061561
[TBL] [Abstract][Full Text] [Related]
6. p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.
Patrussi L; Capitani N; Cattaneo F; Manganaro N; Gamberucci A; Frezzato F; Martini V; Visentin A; Pelicci PG; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncogene; 2018 Mar; 37(11):1534-1550. PubMed ID: 29326436
[TBL] [Abstract][Full Text] [Related]
7. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
[TBL] [Abstract][Full Text] [Related]
8. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
Zhang W; Pelicano H; Yin R; Zeng J; Wen T; Ding L; Huang R
Mol Med Rep; 2015 Nov; 12(5):7374-88. PubMed ID: 26458979
[TBL] [Abstract][Full Text] [Related]
9. Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.
El-Khoury V; Pierson S; Szwarcbart E; Brons NH; Roland O; Cherrier-De Wilde S; Plawny L; Van Dyck E; Berchem G
Leukemia; 2014 Aug; 28(8):1636-46. PubMed ID: 24418989
[TBL] [Abstract][Full Text] [Related]
10. p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
Patrussi L; Capitani N; Ulivieri C; Manganaro N; Granai M; Cattaneo F; Kabanova A; Mundo L; Gobessi S; Frezzato F; Visentin A; Finetti F; Pelicci PG; D'Elios MM; Trentin L; Semenzato G; Leoncini L; Efremov DG; Baldari CT
Haematologica; 2019 Oct; 104(10):2040-2052. PubMed ID: 30819907
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
13. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Kong YL; Pan BH; Liang JH; Zhu HY; Wang L; Xia Y; Wu JZ; Fan L; Li JY; Xu W
Aging (Albany NY); 2020 Aug; 12(16):16083-16098. PubMed ID: 32855355
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Inoue S; Mai A; Dyer MJ; Cohen GM
Cancer Res; 2006 Jul; 66(13):6785-92. PubMed ID: 16818655
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase in chronic lymphocytic leukemia.
Wang JC; Kafeel MI; Avezbakiyev B; Chen C; Sun Y; Rathnasabapathy C; Kalavar M; He Z; Burton J; Lichter S
Oncology; 2011; 81(5-6):325-9. PubMed ID: 22237050
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade.
El-Khoury V; Moussay E; Janji B; Palissot V; Aouali N; Brons NH; Van Moer K; Pierson S; Van Dyck E; Berchem G
Mol Cancer Ther; 2010 May; 9(5):1349-60. PubMed ID: 20406947
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
Buurman R; Sandbothe M; Schlegelberger B; Skawran B
Eur J Med Res; 2016 Jun; 21(1):26. PubMed ID: 27342975
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.
Sampath D; Liu C; Vasan K; Sulda M; Puduvalli VK; Wierda WG; Keating MJ
Blood; 2012 Feb; 119(5):1162-72. PubMed ID: 22096249
[TBL] [Abstract][Full Text] [Related]
20. Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
Zurli V; Wimmer G; Cattaneo F; Candi V; Cencini E; Gozzetti A; Raspadori D; Campoccia G; Sanseviero F; Bocchia M; Baldari CT; Kabanova A
Blood; 2017 Nov; 130(18):2006-2017. PubMed ID: 28931525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
